2,000 patients suing Boehringer over Pradaxa

| | Cardiovascular Business | Heart Rhythm

More than 2,000 patients in the U.S. have filed suits against Boehringer Ingelheim over its oral anticoagulant dabigatran (Pradaxa). The company confirmed the number to Reuters after a German newspaper initially reported the total.

Boehringer facing more than 2,000 U.S. lawsuits over blood thinner

Related Content

Eko Health’s AI platform for digital stethoscopes granted new CPT code
Predicting sudden cardiac death after a heart attack may be impossible—for now
Concomitant ablation surgery during heart operations boosts long-term survival
Johnson & Johnson MedTech gains FDA approval for Varipulse PFA system
Boston Scientific agrees to acquire AFib ablation company
Heart Rhythm Society launches new group focused on EP advocacy

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup